Drugs giant GSK is set to move its global headquarters back to central London, ending more than two decades at its Brentford base. Around 3,000 employees will work from The Earnshaw building on ...

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD).

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D.

GSK developed altSonflex1-2-3 to address the unmet need. Phase 1 and interim phase 2 data met GSK’s immunogenicity success criteria, the London-based drugmaker said. Yet, GSK has decided to hand ...

Hyderabad-based vaccine maker Bharat Biotech International and global biopharma major GSK have announced a collaboration to advance development of latter’s Shigella vaccine candidate altSonflex1 ...